Avantra Biosciences Announces Significant Reduction In Multiplex Immunoassay Processing Time
WOBURN, Mass., June 14, 2011 /PRNewswire/ — AvantraÃ‚® Biosciences, a leading innovator in protein diagnostics, announces that it has reduced assay run time by more than 70% on the Avantra Biomarker System. Researchers can now run assays in as little as 15 minutes depending on customer requirements for antigen sensitivity. Reduced assay run times and the recently announced Rapid Assay Prototyping Service greatly increase the versatility of the Avantra Biomarker System providing researchers and clinicians maximum operational efficiencies.
The Avantra Biomarker System offers users rapid, easy-to-use, quantitative multiplex protein assays using catalog or custom reagents. Avantra’s assays can be used for screening drug targets, pathway analysis, and disease state biomarker profiling. The Avantra Biomarker System is currently being evaluated and used by variety of health care institutions and research organizations for both research and potential point-of-care applications.
About Avantra Biosciences
Avantra Biosciences, a Courtagen Life Sciences Company, is a privately held diagnostics company that has pioneered next-generation technology for protein biomarker analysis. Avantra’s Biomarker System consists of the Q400 Biomarker Workstation and the QPDx(TM) BioChip, which enables scientists and clinicians to perform multiplex biomarker analysis for research use only (RUO) at their lab bench or clinical trial site.
SOURCE Avantra Biosciences